Chang Hyoung Woo, Kim Wook Sung, Ahn Joong Hyun, Carriere Keumhee C, Jeong Dong Seop, Cho Yang Hyun, Sung Kiick, Park Pyo Won
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea.
Department of Thoracic and Cardiovascular Surgery, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Thorac Dis. 2019 Dec;11(12):5372-5381. doi: 10.21037/jtd.2019.11.65.
The present study aimed to compare the long-term clinical and hemodynamic outcomes of aortic valve replacement using Carpentier-Edwards Perimount (Perimount) or Perimount Magna (Magna) valves.
We enrolled 430 patients who underwent aortic valve replacements with Perimount (n=58) or Magna (n=372) valves [1998-2013]. Multivariable and inverse probability of treatment weight (IPTW) analyses were performed.
Before IPTW analysis, the overall 8-year survival rate differed significantly between the groups [Perimount 90%±4% Magna 76%±4%; P=0.02; hazard ratio (HR): 0.37 for the Perimount group; 95% confidence interval (CI): 0.17-0.83]. Multivariable analysis of the overall survival identified Perimount valve use as a protective factor (P=0.009; HR: 0.32; 95% CI: 0.14-0.75). Independent risk factors of overall survival were older age, male sex, higher preoperative left ventricular mass index, lower ejection fraction, lower aortic valve pressure gradient, and lower haemoglobin. After applying IPTW, overall survival was again found to be significantly longer in the Perimount group (P=0.04; HR: 0.43; 95% CI: 0.20-0.93). Event-free survival was also better in the Perimount group (P=0.006; HR: 0.38; 95% CI: 0.19-0.75). However, the Magna group had significantly lower aortic valve pressure gradients at one year and five years postoperative.
Although Magna use led to decreased aortic valve pressure gradients at follow-up, overall and event-free survival rates were significantly better with use of the Perimount valve. Additional and larger studies are needed to confirm these results.
本研究旨在比较使用卡朋特 - 爱德华兹卓越型(卓越型)或卓越加强型(加强型)瓣膜进行主动脉瓣置换术的长期临床和血流动力学结果。
我们纳入了430例在1998年至2013年期间接受卓越型(n = 58)或加强型(n = 372)瓣膜主动脉瓣置换术的患者。进行了多变量分析和治疗权重逆概率(IPTW)分析。
在IPTW分析之前,两组的总体8年生存率存在显著差异[卓越型90%±4%,加强型76%±4%;P = 0.02;风险比(HR):卓越型组为0.37;95%置信区间(CI):0.17 - 0.83]。总体生存的多变量分析确定使用卓越型瓣膜为保护因素(P = 0.009;HR:0.32;95% CI:0.14 - 0.75)。总体生存的独立危险因素为年龄较大、男性、术前左心室质量指数较高、射血分数较低、主动脉瓣压力阶差较低和血红蛋白较低。应用IPTW后,再次发现卓越型组的总体生存时间显著更长(P = 0.04;HR:0.43;95% CI:0.20 - 0.93)。卓越型组的无事件生存率也更好(P = 0.006;HR:0.38;95% CI:0.19 - 0.75)。然而,加强型组在术后1年和5年时的主动脉瓣压力阶差显著更低。
尽管使用加强型瓣膜在随访时导致主动脉瓣压力阶差降低,但使用卓越型瓣膜时总体生存率和无事件生存率显著更好。需要更多更大规模的研究来证实这些结果。